Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies.
Stephen M. Ansell,Michael B. Maris,Alexander M. Lesokhin,Robert W. Chen,Ian W. Flinn,Ahmed Sawas,Mark D. Minden,Diego Villa,Mary-Elizabeth M. Percival,Anjali S. Advani,James M. Foran,Steven M. Horwitz,Matthew G. Mei,Jasmine Zain,Kerry J. Savage,Christiane Querfeld,Oleg E. Akilov,Lisa D. S. Johnson,Tina Catalano,Penka S. Petrova,Robert A. Uger,Eric L. Sievers,Anca Milea,Kathleen Roberge,Yaping Shou,Owen A. O'Connor Clinical Cancer Research（2021）
Key words
Cancer Immunotherapy
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper